Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, we believe Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity in various age-related and muscular wasting conditions.


Our preclinical studies have demonstrated that Sarconeos (BIO101) activates the MAS receptor in muscle cells, a key component of the Renin-Angiotensin System (RAS). The RAS is a fundamental endocrine system that is known to control fluid balance, blood pressure and cardio-vascular function. The RAS is also involved in the regulation of smooth, cardiac and skeletal muscle metabolism and plays a key role in muscle function and mobility in disease states.

The mechanism-of-action of Sarconeos (BIO101) is illustrated below:

Sarconeos (BIO101) MAS Receptor

Sarconeos (BIO101) triggers two important MAS receptor downstream signaling-pathways in myocytes that are impaired in many muscle wasting conditions:

  • P13K/AKT/mTOR pathway – Increases protein synthesis, preserving muscle mass and increasing muscle strength
  • AMPK/ACC pathwayStimulates energy production, increasing muscle strength and mobility

MAS activation in skeletal and smooth muscles stimulates muscle metabolism and strength with a potential impact on mobility or respiratory functions.